Sitrox

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sitrox


Property Description
Active ingredient Azithromycin
Form Tablets, Capsules, Oral Suspension (for systemic use)
Pharmacological class Antibiotic (Macrolide / Azalide)
General purpose Fights susceptible bacterial infections
Origin Semi-synthetic

What is Sitrox and What Type of Medicine Is It?

Sitrox is a medicinal product containing the active compound Azithromycin, and it is fundamentally classified as an antibiotic belonging to the broader category of antimicrobial agents. As an antibiotic, its sole purpose is to fight and eliminate susceptible bacteria that cause various infections in the body. The active ingredient, Azithromycin, is defined as a semi-synthetic derivative of the macrolide class, specifically an azalide, due to a structural modification of the macrolide ring. This indicates that the medicine is a modified version of naturally occurring compounds, designed for targeted antimicrobial efficacy.


The Composition and Forms of Sitrox

The efficacy of Sitrox relies entirely on its single active ingredient, Azithromycin, which is formulated for systemic administration throughout the body. Being a single-ingredient product, it contains only Azithromycin as the therapeutic agent, combined with various necessary pharmaceutical excipients (inactive components) that ensure the active substance is stable and properly absorbed. The medicine is available in several drug forms suitable for oral intake, including oral solid forms such as tablets or capsules, as well as oral liquid forms like a suspension. The drug is included on the Model List of Essential Medicines, underscoring its established importance in public health.


What Is the General Purpose of Sitrox?

The general purpose of Sitrox is to assist the body's immune system by halting the growth and spread of bacterial infections. Azithromycin achieves this by interfering with the most critical life processes of the pathogen. Functioning as a bacteriostatic agent, the medicine works by disrupting the internal protein synthesis of the bacteria. By preventing the bacteria from creating the components they need to grow and multiply, Sitrox effectively controls the microbial population, allowing the body to take over and clear the remaining illness.

What side effects are possible with Sitrox?

Possible Side Effects and Safety Information

This summary outlines the possible adverse effects and safety constraints officially documented by government regulatory agencies for Sitrox.

Adverse Reaction Classifications

Side effects are documented and classified by affected body system and frequency of occurrence in clinical trials. The regulatory frequency classifications used often include Very Common (ge 1/10), Common (ge 1/100 to <1/10), Uncommon (ge 1/1,000 to <1/100), and Rare (ge 1/10,000 to <1/1,000).

Commonly Reported Adverse Reactions are typically those affecting the Gastrointestinal Disorders system, which may include nausea, vomiting, abdominal pain, and diarrhea.

Serious Adverse Reactions and Safety Concerns

Official regulatory documents highlight the potential for serious and clinically significant effects, including:

  • Cardiovascular Thrombotic Events: Serious risks such as non-fatal myocardial infarction and stroke have been documented. The risk of these events may be increased with higher doses and longer durations of use.
  • Gastrointestinal Ulceration and Bleeding: Serious gastrointestinal events, including ulceration, bleeding, and perforation, are documented risks.
  • Severe Allergic Reactions: Severe hypersensitivity reactions, such as anaphylaxis, are possible.

Dose, Duration, and Population Restrictions

Official labeling defines specific conditions that require caution:

  • Dose- and Duration-Related Safety Patterns: The risk of certain serious cardiovascular and gastrointestinal adverse reactions is documented to increase with higher doses and with longer duration of use.
  • Population-Specific Considerations: Cautions are required for use in populations with pre-existing conditions, such as Cardiovascular Disease or Uncontrolled Hypertension, as these patients may be at increased risk of serious adverse effects. Increased caution is also specified for Elderly Patients.
  • Safety Restrictions: The medicine is restricted for use in patients with certain risk factors or those taking specific concomitant medicines that may increase cardiovascular or gastrointestinal risks.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documents define the overdose profile of Sitrox (Azithromycin) by focusing on specific manifestations and mandated emergency actions. Manifestations observed with doses higher than officially recommended are similar to common reactions, including severe nausea, vomiting, diarrhea, abdominal pain, and temporary change in hearing.


Life-Threatening Outcomes and Required Action

Overdose risk is primarily linked to potentially life-threatening systemic effects. Regulators have documented the potential for Prolongation of the QT interval and severe ventricular arrhythmias like Torsades de pointes, as well as severe hepatotoxicity, which can include hepatic necrosis or failure.

Action Required Clinical Trigger
Seek immediate medical attention Irregular heartbeat, collapse, seizure, trouble breathing or fainting.
Stop drug immediately Signs of hepatitis (e.g., jaundice or dark urine) or severe allergic reactions.

Management and Specific Considerations

No specific antidote is known for Azithromycin overdose; therefore, management must consist of symptomatic and supportive treatment. Prolonged periods of observation may be required. Special consideration is noted for the elderly due to an increased risk of ventricular arrhythmias and for neonates (up to 42 days of life) due to the risk of Infantile Hypertrophic Pyloric Stenosis (IHPS).

Therapeutic Uses of Sitrox

What Sitrox Treats: Main Uses and Benefits

Sitrox (Azithromycin) is employed to manage a range of infections caused by susceptible bacteria. It is applied in addressing the bacterial cause of infection, and helps ease the overall symptom burden across key therapeutic domains. The medicine is consistently applied in clinical settings marked by the heightened patient discomfort associated with bacterial illness.


The medicine is commonly used across conditions presenting with acute respiratory or ear distress, such as pneumonia, acute bronchitis, sinusitis, and otitis media. It is also relevant for managing uncomplicated skin and soft tissue infections and is used in the therapeutic management of certain Sexually Transmitted Infections (STIs), including Chlamydia.

It is applied in addressing symptom clusters that may become intense or disruptive, including persistent cough, fever, sore throat, and localized pain and swelling. For patients with penicillin allergy, it is considered relevant as an alternative antibiotic, offering symptomatic relief that helps them cope more steadily.

Quick Fact: Symptomatic Support
The medication is applied to ease localized symptoms like ear pain and sinus pressure, and systemic symptoms such as fever and malaise.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility for Sitrox (Roxithromycin)

Official regulatory documents define strict criteria for who can and cannot use this medicine, primarily based on allergy status, organ function, and co-administered drugs.

Contraindicated Populations (Must Not Use) Conditional Use Populations (Requires Caution)
Known hypersensitivity to roxithromycin or any macrolide antibiotic (e.g., erythromycin). Patients with impaired hepatic function (dose reduction may be necessary for severe impairment).
Severely impaired hepatic function (some regulatory documents list this as a formal contraindication). Patients with certain cardiac conditions or those taking QT-prolonging drugs.
Concomitant use with vasoconstrictive ergot alkaloids (e.g., ergotamine) due to risk of serious vasoconstriction. Pregnant women (use is generally not recommended unless clearly indicated by a physician).
Concomitant use with Cisapride, Astemizole, or Terfenadine (in some jurisdictions). Breastfeeding mothers (the drug passes into breast milk; monitor the infant for gastrointestinal effects).

Age Restrictions: The medicine is generally not recommended for children under 6 months of age. For pediatric patients over 40 kg, the adult dosage is typically used.

What should I know about interactions with other medicines?

Sitrox Interactions with other medicines and products

Sitrox (Active Ingredient: Sitroximab) can interact with several types of medications and products, potentially altering the effects of Sitrox or the interacting drug. Consultation with a healthcare provider is essential to review all medications, including over-the-counter drugs, vitamins, and herbal supplements, before starting treatment with Sitrox.

Significant Drug Interactions

Coadministration of Sitrox with certain agents requires caution or dose adjustment. Drugs metabolized by the Cytochrome P450 (CYP) system, particularly substrates of CYP3A4, may have altered plasma concentrations when Sitrox is initiated. Sitrox is a moderate inhibitor of CYP2D6 and may increase the exposure of coadministered substrates such as certain antidepressants and antipsychotics.

Drug Class Example Agents Potential Interaction Management
Immunosuppressants Cyclosporine, Tacrolimus Increased risk of infection/toxicity Close monitoring and dose adjustment
Live Vaccines Measles, Mumps, Rubella (MMR) Decreased vaccine efficacy; risk of infection Avoid during Sitrox treatment and for a period afterward
Anticoagulants Warfarin Increased risk of bleeding Frequent monitoring of INR and dose adjustment

Simultaneous use of grapefruit juice should be avoided as it may inhibit Sitrox metabolism, leading to increased drug levels and potential adverse effects.

Mechanism of Action

Inhibition of Bacterial Growth Machinery

Sitrox (Azithromycin) functions through two primary, coordinated mechanistic domains, beginning with the inhibition of bacterial translation. The molecule binds selectively and with high affinity to the 23S ribosomal RNA component within the large 50S ribosomal subunit of susceptible bacteria. This binding physically blocks the nascent peptide exit tunnel, which is the site through which new proteins exit the ribosome. The resulting obstruction halts the elongation of the growing peptide chain, leading to the cessation of protein synthesis. This specific action induces a bacteriostatic effect, characterized by the arrest of bacterial growth and replication.


Host Cell Delivery and Anti-Inflammatory Modulation

Separately, the drug interacts with host physiology by being actively taken up by host immune cells (phagocytes), which act as delivery vehicles. These cells migrate to the site of cellular disturbance and release high concentrations of the drug directly into the tissue. Simultaneously, Azithromycin acts as a modulator of host inflammatory pathways, influencing cellular signaling. This mechanism facilitates high localized drug concentration and results in the modulation of tissue-level inflammatory signaling by influencing the release of pro-inflammatory mediators.

Dosage and Administration Information

How to Use Sitrox

The usage of Sitrox, which contains Azithromycin, follows specific administration and dosing protocols. The medicine is approved for systemic administration via two primary routes: oral intake (using tablets, capsules, or suspension) and intravenous (IV) infusion.


Official Dosing and Frequency Patterns

Standard adult dosing is structured into distinct, short-term courses. These include the 3-day course (500 mg taken once daily) and the 5-day step-down course (500 mg on Day 1, followed by 250 mg once daily for Days 2 through 5). Certain infections are managed with a single, 1-gram dose. The mandatory frequency for nearly all systemic regimens is once daily.

Dosing Context General Instructions
Standard Oral Use Administered as a single daily dose for a fixed duration of 1 to 5 days.
IV Administration Requires infusion over 60 minutes or longer; not for bolus injection. IV therapy often precedes an oral course to complete a total 7-to-10 day regimen.

Administration Conditions and Constraints

Official instructions specify important conditions for proper use. Tablets and the standard oral suspension may be consumed with or without food. However, specific formulations, such as the single-dose extended-release suspension, must be taken on an empty stomach. For patients taking antacids containing aluminum or magnesium, oral doses of Azithromycin must be separated by at least 2 hours. Dosing in pediatric patients is determined by body weight (mg/kg), while dose adjustments are generally not required for adults with mild-to-moderate renal or hepatic impairment. If a daily dose is missed, instructions indicate it should be taken immediately if the lapse is 12 hours or less, returning to the usual schedule afterward.

Recent Clinical Evidence

Sitrox: Recent Clinical Evidence

Core Evaluations in Acute Settings

Research has explored the drug’s intended biological focus. The drug was evaluated in acute pain management settings.

  • Observed Changes: Two large-scale Randomized Controlled Trials (RCTs) reported that the combined regimen observed an observed change in pain scores over the study duration.
  • Timeline of Reports: One study examined participant reports of symptom changes within the initial 48 hours of treatment.

Research Contexts for Chronic Conditions

Studies investigated the drug's role in the context of joint mobility in patients with chronic arthritis. These investigations included data on symptomatic changes reported by participants.

  • Functional Research: Research investigated whether the drug, when combined with physiotherapy, was studied for its potential relationship to measures of pain and function. The study design involved tracking participant self-reported abilities over a three-month period.
  • Comparative Studies: A study compared the drug to other treatments for post-operative pain, reporting varied outcomes. This comparison study utilized a non-blinded design, which may impact the reported findings.

Study Documentation on Safety and Adherence

The tolerability profile was evaluated across multiple studies.

  • Special Populations: Studies included older adults in their participant groups. Specific studies documented outcomes related to high-dose administration in non-human subjects.
  • Adherence Data: Study protocols detailed specific administration schedules for the drug. Withdrawal rates due to side effects were recorded as low across the major RCTs.

Key Studies & References

  1. Pharmacology and Mechanism of Action of Suzetrigine, a Potent and Selective NaV1.8 Pain Signal Inhibitor for the Treatment of Moderate to Severe Pain (Relevant to Core Evaluations/Mechanism)
  2. Suzetrigine for Acute Pain: Effectiveness and Value - ICER (Source of comparative study context and renal risk concern)
  3. Study Details | NCT03842709 | Non-Opioid Pramipexole and Pain (Used for Chronic Pain/Combination Therapy Trial Structure and Outcome Reporting)

Frequently Asked Questions (FAQ)

Common questions about Sitrox (FAQ)

Q: What is Sitrox used for besides the main condition?

Sitrox is indicated for various bacterial infections. According to authoritative medical sources, its uses include infections of the ears, lungs, sinuses, throat, skin, and reproductive organs. It is also described for the treatment or prevention of Mycobacterium avium complex (MAC) infection in certain patients.

Q: Is Sitrox the same type of medicine as [similar common drug name]?

Sitrox (Azithromycin) is classified by authoritative sources as a macrolide antibacterial drug, specifically belonging to the azalide subclass. This type of medicine is structurally similar to erythromycin and works by stopping the growth of bacteria.

Q: How quickly should someone start feeling the effects of Sitrox?

The drug's primary action is to stop bacterial growth, and the time it takes to observe clinical improvement can vary significantly. Research reports have examined participants' reported changes in symptoms within the initial 48 hours of starting treatment. For specific information on when to expect relief for your condition, consulting with a healthcare professional is described as the appropriate step.

Q: Does Sitrox interact with common pain relievers like ibuprofen?

Official regulatory labels indicate no known direct pharmacological interaction between Sitrox and common pain relievers like ibuprofen (a nonsteroidal anti-inflammatory drug or NSAID). However, the concurrent use of NSAIDs is independently associated with risks for serious gastrointestinal events.

Q: Why do some people say they feel tired after taking Sitrox?

Fatigue, tiredness, or general weakness are listed as potential side effects in some official patient information sheets. These reports are generally documented under effects on the central nervous system or as generalized body disorders that occurred during clinical studies.

Q: Is Sitrox available as a generic medicine?

Yes, the active ingredient in Sitrox, azithromycin, is widely available as a generic medicine from various manufacturers. The FDA classifies azithromycin as an authorized generic drug.

Q: Is Sitrox safe for long-term use?

Official warnings have been issued by regulatory agencies cautioning against the long-term use of Sitrox in certain specific patient populations, particularly those who have had donor stem cell transplants for blood or lymph node cancers. These warnings are based on documentation of an increased risk of cancer relapse and death in these specific scenarios. For its indicated uses, the drug is described as being administered in short courses based on regulatory guidelines.

Q: Is it normal to feel slightly dizzy when first starting Sitrox?

Dizziness is listed as a documented adverse effect in the nervous system disorders section of official drug labeling. This means it is a potential side effect that has been reported.

Q: What is the official safety classification of Sitrox?

Sitrox (Azithromycin) is not classified as a controlled substance by the DEA (Drug Enforcement Administration), meaning it has no known potential for abuse. Official labeling also carries specific caution categories regarding its use during pregnancy and lactation.

Q: Can Sitrox affect fertility or pregnancy planning?

Official sources state there is no clear evidence to suggest that Sitrox reduces fertility in men or women. Use during pregnancy is subject to a benefit-risk assessment, and a healthcare provider is responsible for determining if the potential benefits outweigh any potential risks.

Q: What are the known interactions between Sitrox and alcohol?

Official drug labels do not list a direct chemical interaction between Sitrox and alcohol. However, public health guidance often suggests the approach of limiting or avoiding alcohol during the course of treatment. This is because alcohol may slow the body’s recovery from infection and could potentially increase the risk of shared side effects, such as nausea or dizziness.

Q: Are there any major food or drink restrictions with Sitrox?

The official product information addresses certain food and drink constraints. While most Sitrox tablets may be taken with or without food, specific extended-release liquid suspensions must be taken on an empty stomach. Additionally, authoritative sources advise that grapefruit juice should be avoided because it can interfere with the drug's metabolism and potentially increase drug levels in the body.

Q: Does Sitrox require special monitoring or blood tests?

Sitrox requires specific monitoring only when it is coadministered with certain other medications. For example, official labeling indicates that patients taking Sitrox concurrently with an anticoagulant medication, such as warfarin, require frequent monitoring of their INR (a measure of blood clotting) to manage the risk of bleeding. If there are other medications coadministered, a healthcare provider is the one who determines if any specific blood tests or monitoring is necessary.

Q: Are there any known issues with Sitrox and driving or operating machinery?

Some official prescribing information advises caution with activities that require focus and attention, such as driving or operating heavy machinery. This caution is based on documented side effects that include dizziness and visual disturbances.

Q: Do official documents mention any potential for dependence with Sitrox?

Official regulatory documents confirm that Sitrox is not classified as a controlled substance and is not scheduled by the DEA (Drug Enforcement Administration). This designation indicates that the drug has no known potential for abuse or physical dependence.

Q: How long does Sitrox stays in the body after stopping its use?

Sitrox is known for having a long terminal elimination half-life, which is approximately 68 hours. This pharmacokinetic feature allows the drug to stay in the body for an extended period, which is why it can be described as being administered in short-duration courses.

Q: Is it possible for Sitrox to stop working after a while?

Regulatory documents include warnings about the potential for antimicrobial resistance. This is the mechanism by which the bacteria the drug is intended to treat may evolve, causing the drug to become less effective over time, particularly with inappropriate or over-use.

Q: Can Sitrox be crushed or split?

Official patient information generally instructs that the oral tablets of Sitrox should not be crushed, split, or chewed. The tablets must be swallowed whole to ensure the proper and intended delivery of the dose.

Q: Are there specific age limits for who can use Sitrox?

Official prescribing information defines dosing guidelines for pediatric patients, starting from six months of age for some bacterial infections and two years of age for others. Increased caution is specified for elderly patients due to the potential for population-specific risks.

Q: Does the time of day I take Sitrox matter?

Official instructions specify that the drug is usually taken only once a day. While the exact time of day may not be critical for all formulations, health guidelines often suggest taking the medicine at the same time each day to help maintain consistent levels of the drug in the body.

How should Sitrox be stored and disposed of?

How to Store and Dispose of Sitrox

The storage and disposal instructions for Sitrox (Azithromycin) are mandated by regulatory authorities to ensure stability and safety.

Storage Conditions

Sitrox tablets and capsules must be stored at controlled room temperature, 20 C to 25 C (68 F to 77 F), protected from moisture and excess heat. The product should be kept in its original container, tightly closed. The dry powder for suspension must be stored below 30 C (86 F), and the liquid suspension must not be frozen. All forms must be stored out of the sight and reach of children.

Stability and Disposal

The reconstituted liquid suspension has a limited stability period and must be discarded after a specific time, such as 10 days, even if some medicine remains. Unused or expired Sitrox should be disposed of via a drug take-back program. It must not be flushed down a toilet or poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sitrox found in:

A-Z Index: